Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8092326 | 1.00 | SIGMAR1 (0.74) | SIGMAR1MEN1KMT2AL3MBTL1SLC2A1 | |
| SCHEMBL2795948 | 1.00 | SIGMAR1 (0.74) | SIGMAR1MEN1KMT2AL3MBTL1SLC2A1 | |
| SCHEMBL593666 | 1.00 | SIGMAR1 (0.74) | SIGMAR1MEN1KMT2AL3MBTL1SLC2A1 | |
| Hydrochloric Acid SCHEMBL1134234 | 0.98 | SIGMAR1 (0.72) | SIGMAR1MEN1KMT2AL3MBTL1SLC2A1 | |
| Hydrochloric Acid SCHEMBL1134233 | 0.98 | SIGMAR1 (0.72) | SIGMAR1MEN1KMT2AL3MBTL1SLC2A1 | |
| SCHEMBL3341840 | 0.92 | SIGMAR1 (0.62) | SIGMAR1MEN1KMT2AL3MBTL1SLC2A1 | |
| SCHEMBL3341844 | 0.92 | SIGMAR1 (0.62) | SIGMAR1MEN1KMT2AL3MBTL1SLC2A1 | |
| SCHEMBL3346880 | 0.92 | SIGMAR1 (0.62) | SIGMAR1MEN1KMT2AL3MBTL1SLC2A1 | |
| SCHEMBL6539539 | 0.89 | SIGMAR1 (0.59) | SIGMAR1MEN1KMT2AL3MBTL1SLC2A1 | |
| SCHEMBL3630860 | 0.88 | SIGMAR1 (0.57) | SIGMAR1MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114544809-B | HPLC (high performance liquid chromatography) detection method for chiral purity of arformoterol intermediate and enantiomer thereof | 汉瑞药业(荆门)有限公司 | 2022-12-09 | — | — | CN | claimed |
| CN-114456078-B | Preparation method of (R) -N-benzyl-1- (4-methoxyphenyl) propyl-2-amine | 汉瑞药业(荆门)有限公司 | 2022-09-16 | — | — | CN | claimed |
| CN-114456078-A | Preparation method of (R) -N-benzyl-1- (4-methoxyphenyl) propan-2-amine | 汉瑞药业(荆门)有限公司 | 2022-05-10 | — | — | CN | claimed |
| CN-114456078-B | Preparation method of (R) -N-benzyl-1- (4-methoxyphenyl) propyl-2-amine | 汉瑞药业(荆门)有限公司 | 2022-09-16 | — | — | CN | disclosed |
| CN-114456078-B | Preparation method of (R) -N-benzyl-1- (4-methoxyphenyl) propyl-2-amine | 汉瑞药业(荆门)有限公司 | 2022-09-16 | — | — | CN | disclosed |
| CN-114456078-B | Preparation method of (R) -N-benzyl-1- (4-methoxyphenyl) propyl-2-amine | 汉瑞药业(荆门)有限公司 | 2022-09-16 | — | — | CN | disclosed |
| CN-114456078-A | Preparation method of (R) -N-benzyl-1- (4-methoxyphenyl) propan-2-amine | 汉瑞药业(荆门)有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-114456078-A | Preparation method of (R) -N-benzyl-1- (4-methoxyphenyl) propan-2-amine | 汉瑞药业(荆门)有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-114456078-A | Preparation method of (R) -N-benzyl-1- (4-methoxyphenyl) propan-2-amine | 汉瑞药业(荆门)有限公司 | 2022-05-10 | — | — | CN | disclosed |
| US-10925840-B2 | Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-02-23 | — | — | US | disclosed |
| US-20200197332-A1 | USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-06-25 | — | — | US | disclosed |
| US-6268533-B1 | REACTING 4-BENZYLOXY-3-FORMAMIDOSTYRENE OXIDE WITH AN OPTICALLY PURE 4-METHOXY-.ALPHA.-METHYL-N-(PHENYLMETHYL)BENZENEETHANAMINE FOLLOWED BY REDUCTION TO PRODUCE FORMOTEROL | SEPRACOR INC. | 2001-07-31 | — | — | US | disclosed |
| EP-1093450-A1 | DESFORMOTEROL AND PROCESS FOR ITS PREPARATION | Sepracor Inc. (US) | 2001-04-25 | — | — | EP | disclosed |
| WO-2000067741-A2 | (S,R) FORMOTEROL METHODS AND COMPOSITIONS | SEPRACOR INC. (US) | 2000-11-16 | — | — | WO | disclosed |
| US-6071971-A | FOR TREATING PULMONARY DISORDERS | SEPRACOR INC. (US) | 2000-06-06 | — | — | US | disclosed |
| US-6040344-A | CRYSTALLINE R,R-FORMOTEROL L-(+)-TARTRATE. | SEPRACOR INC. (US) | 2000-03-21 | — | — | US | disclosed |
| WO-1999067198-A1 | DESFORMOTEROL AND PROCESS FOR ITS PREPARATION | SEPRACOR INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| US-5965622-A | BRONCHODILATORS; HIGHLY SELECTIVE BETA 2-ADRENERGIC RECEPTOR AGONIST; RESPIRATORY DISORDERS, E.G. ASTHMA, BRONCHITIS; REDUCTION OF A PROTECTED NITRO DERIVATIVE; STEREOSPECIFIC | SEPRACOR INC. (US) | 1999-10-12 | — | — | US | disclosed |
| EP-0938467-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY PURE ISOMERS OF FORMOTEROL | SEPRACOR, INC. (US) | 1999-09-01 | — | — | EP | disclosed |
| WO-1998021175-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY PURE ISOMERS OF FORMOTEROL | SEPRACOR, INC. (US) | 1998-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200197332-A1 | USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | ADRB2, ADRB1, ADRA2A | SIGMAR1 363/4885MEN1 1082/4885KMT2A 3251/4885 |
| US-10925840-B2 | Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | ADRB2, ADRB1, ADRA2A | SIGMAR1 363/4885MEN1 1082/4885KMT2A 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.